Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective multicenter observational study of hydromorphone conversion rate in cancer patients
jRCT1040230173Recruiting
- Sponsor
- Japanese Society for Pharmaceutical Palliative Care and Sciences
- Start
- Mar 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of hydromorphone in cancer pain, sponsored by Japanese Society for Pharmaceutical Palliative Care and Sciences. Primary endpoint: Conversion rate of hydromorphone. Started Mar 2024; status: recruiting.
02
Drugs
hydromorphone
03
Conditions
cancer pain
Beyond the preview
Go deeper on jRCT1040230173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1040230173.